Q-omics provides the consensus-scored RDXP2 profile across patient tissues and cancer cell-line models. RDXP2 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, RDXP2 is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, RDXP2 RNA expression shows 4,675 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BLCA, KIRC, and STAD as cancer lineages where RDXP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RDXP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RDXP2 survival associations across molecular data types. RDXP2 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RDXP2 RNA expression–survival associations across cancer types. High RDXP2 expression shows unfavorable associations in BLCA, CHOL, LUAD, STAD, UCS and THYM. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for RDXP2 RNA expression.
This table summarizes RDXP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for RDXP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RDXP2 shows higher tumor expression in KIRC. The KIRC box plot shows higher RDXP2 RNA expression in tumor versus normal tissue (log2 FC = +0.067, t-test p = .021).
This table shows molecular features associated with RDXP2 in patient tissues and cancer cell lines. In patient samples, RDXP2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
